HCID 44541677, compound → HCID 25253835, compound

HRID 1365784Notes

Reaction equation

HRID 1365784 reaction equation
C(O[C:6](=O)[N:7]([C:9]1[CH:14]=[CH:13][C:12]([C:15]2[N:16]=[C:17]([N:35]3[CH2:40][CH2:39][O:38][CH2:37][CH2:36]3)[C:18]3[N:23]=[C:22]([CH2:24][N:25]4[CH2:30][CH2:29][N:28]([S:31]([CH3:34])(=[O:33])=[O:32])[CH2:27][CH2:26]4)[S:21][C:19]=3[N:20]=2)=[CH:11][N:10]=1)C)(C)(C)C>FC(F)(F)C(O)=O.ClCCl>[CH3:6][NH:7][C:9]1[CH:14]=[CH:13][C:12]([C:15]2[N:16]=[C:17]([N:35]3[CH2:40][CH2:39][O:38][CH2:37][CH2:36]3)[C:18]3[N:23]=[C:22]([CH2:24][N:25]4[CH2:30][CH2:29][N:28]([S:31]([CH3:34])(=[O:33])=[O:32])[CH2:27][CH2:26]4)[S:21][C:19]=3[N:20]=2)=[CH:11][N:10]=1

Participants

4

Procedure

Crude {5-[2-(4-methanesulfonyl-piperazin-1-ylmethyl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-5-yl]-pyridin-2-yl}-methyl-carbamic acid tert-butyl ester 75 (100 mg) was dissolved in a solution of 1 mL of trifluoroacetic acid and 1 mL of dichloromethane. The reaction mixture was stirred for 1 h. The mixture was concentrated. The product was purified by reverse phase HPLC to yield 53.8 mg of 101. MS (Q1) 505.2 (M)+.

Workup

  1. concentrationThe mixture was concentrated
  2. customThe product was purified by reverse phase HPLC

Sources & evidence

ORD record
ord-6d1c9f69fae043f180cabc7b736bbcab
Source dataset
uspto-grants-2011_02
Patent number
US07893059B2

Reaction notes

Loading…